GLIA Integrated Healthcare introduces gentler, non-invasive approach to cancer Care

The groundbreaking approach, leveraging Rotational Field Quantum Magnetic Resonance (RFQMR) to produce modulated Fast Radio Bursts (FRB)

Glia Integrated Healthcare has introduced Cytotron therapy, which claims to be a new ray of hope for cancer patients seeking a gentler, non-invasive approach to cancer care. 

In the relentless battle against cancer, the quest for more effective and less invasive treatments has led to significant scientific breakthroughs. Among the most promising innovations in this domain is Cytotron therapy, a non-invasive technology that has opened new frontiers in cancer care. This groundbreaking approach, leveraging Rotational Field Quantum Magnetic Resonance (RFQMR) to produce modulated Fast Radio Bursts (FRB), the therapeutic signal to regulate the behavior of proteins in the cancer cells, offers a beacon of hope for those navigating the challenging journey of cancer treatment.

Cytotron therapy emerges as a revolutionary approach, marking a paradigm shift from traditional cancer treatments. This technology targets cancerous cells directly, aiming to inhibit their growth and reduce metastasis, all while preserving the integrity of surrounding healthy tissues. 

In the pursuit of innovative solutions for cancer treatment, Cytotron has emerged as a groundbreaking technology with the potential to reshape the landscape of oncology. The Centre for Devices and Radiological Health (CDRH), United States Food and Drug Administration (US-FDA), recognized the Cytotron as a Breakthrough Device for the treatment of Breast, Pancreas and Liver Cancers, for conducting a clinical trial to establish that it is better than existing standards of care for these indications. The Breakthrough Device designation allows Fast-track the path to market authorization for use in the US. 

Cytotron was invented in India by Dr Rajah Vijaya Kumar, Group Chairman of Organization de Scalene, Director and Chief Scientific Officer, Centre for Advanced Research and Development (CARD), Bengaluru India. He holds the worldwide patent for the device.

 Cytotron’s designation as a Breakthrough Device signifies its transformative impact on cancer care.

Cytotron has evolved using Magnetic Resonance Imaging (MRI) based on intrinsic proton density (PD) measurements of the target tissue to manipulate biophysical cellular signalling. Highly complex Fast Radio Bursts (FRB) in the safe radio frequency range, in the presence of controlled, high, instantaneous Magnetic Resonance, is precisely focused on target tissues to alter the Transmembrane potential (TMP) of cells which triggers apoptosis (programmed cell death) and stops growth of solid tumors. 

The science behind Cytotron therapy is as fascinating as it is hopeful. Cytotron is intended to non-invasively re-activate the body’s tumour suppression mechanism by targeting high precision and calibrated doses of fast radio bursts (FRB) – non-ionising, non-thermal electromagnetic FRBs at the tumour site. This triggers the production of new tumour-suppressing nucleoproteins, predominantly upregulating p53, which determines and flags that the cell is old enough to die.

Dr Anjana Nair, Medical Director, Glia Integrated Healthcare, Bengaluru and a leading expert in Cytotron therapy at Glia, highlights the potential benefits, “it’s painless, avoids harsh side effects, non-toxic and can improve a patient’s quality of life.”